PRF Technologies FDA clears IND for OcuRing-K Phase II trial
PRF Technologies said the FDA cleared the IND for OcuRing™-K, enabling a U.S. multi-center Phase II trial in cataract surgery. Patient enrollment is expected in the second half of 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.